## 1,2,3,4-Tetrahydro-1-methyl-beta-carboline-1-carboxylic acid (THβC)
**THβC** is a heterocyclic compound, specifically a beta-carboline derivative. It's formed naturally in the body through the reaction of tryptophan and formaldehyde. This reaction can be enhanced by the presence of alcohol, leading to its potential role in alcohol-related health issues.
**Why is THβC important for research?**
THβC has garnered significant attention in research due to its potential involvement in several physiological and pathological processes:
**1. Neurotoxicity:** THβC has been implicated in **neurotoxicity**, particularly in the context of alcohol consumption. Studies have shown that chronic alcohol consumption increases THβC levels in the brain. This buildup is linked to neuronal damage and may contribute to alcohol-related neurodegenerative disorders like Wernicke-Korsakoff syndrome.
**2. Oxidative Stress:** THβC is known to generate **reactive oxygen species (ROS)**, leading to oxidative stress. This oxidative stress can contribute to cellular damage and various diseases, including Alzheimer's disease and Parkinson's disease.
**3. Potential Anti-Cancer Effects:** While THβC has been linked to neurotoxicity, some studies suggest it may also possess **anti-cancer properties**. It has been shown to inhibit the growth of certain cancer cell lines in vitro. However, more research is needed to understand its full potential in cancer treatment.
**4. Other Research Areas:** THβC research also extends to its involvement in:
* **Schizophrenia:** Some studies suggest a link between THβC and the development of schizophrenia.
* **Depression:** Research into THβC's potential role in depression is ongoing.
* **Sleep Regulation:** THβC may influence sleep patterns, but further investigation is required.
**Overall, THβC is a complex compound with multifaceted biological effects. Understanding its role in these processes is crucial for developing new therapeutic strategies and preventing health issues associated with alcohol consumption and other conditions.**
**It's important to note that research on THβC is still ongoing, and its exact mechanisms of action and therapeutic potential remain under investigation.**
1,2,3,4-tetrahydro-1-methyl-beta-carboline-1-carboxylic acid: condensation product of pyruvic acid and tryptamine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 98375 |
SCHEMBL ID | 9480993 |
MeSH ID | M0147857 |
Synonym |
---|
EU-0013713 |
1-methyl-2,3,4,9-tetrahydro-1h-beta-carboline-1-carboxylic acid |
IDI1_002954 |
6543-83-5 |
nsc-115069 |
nsc115069 |
CHEMDIV2_004239 , |
AKOS000274712 |
HMS1381A15 |
1-methyl-2,3,4,9-tetrahydropyrido[3,4-b]indole-1-carboxylic acid |
1-methyl 1,2,3,4-tetrahydro-beta-carboline-1-carboxylic acid |
einecs 229-459-7 |
2,3,4,9-tetrahydro-1-methyl-1h-pyrido(3,4-b)indole-1-carboxylic acid |
1,2,3,4-tetrahydro-1-methyl-beta-carboline-1-carboxylic acid |
nsc 115069 |
CCG-21968 |
FT-0676732 |
AKOS016037557 |
SCHEMBL9480993 |
SR-01000505255-1 |
sr-01000505255 |
2,3,4,9-tetrahydro-1-methyl-1h-pyrido[3,4-b]indole-1-carboxylic acid |
1-methyl-2,3,4,9-tetrahydro-1h-beta-carboline-1-carboxylic acid, aldrichcpr |
1,2,3,4-tetrahydro-1-methyl-b-carboline-1-carboxylic acid |
mfcd00227839 |
1-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole-1-carboxylic acid |
1-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole-1-carboxylicacid |
CS-0319639 |
DTXSID501158348 |
1-methyl-1h,2h,3h,4h,9h-pyrido[3,4-b]indole-1-carboxylic acid |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (60.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.60) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |